Carlina-M 2.5/1000 Tablet

About Carlina-M 2.5/1000 Tablet

The tablet Carlina-M 2.5/1000 contains Linagliptin + Metformin Hydrochloride and is made by Radiant Pharmaceuticals Ltd. It is chosen when treatment with both linagliptin and metformin hydrochloride together is suitable for the person.

There are 31 brands of Linagliptin + Metformin Hydrochloride listed in Bangladesh. 8 of them have a lower unit price than Carlina-M 2.5/1000. The lowest listed price is Linatin M 2.5 mg + 500 mg Tablet at ৳ 7.00 per unit.

What is Carlina-M 2.5/1000 Tablet?

Made by Radiant Pharmaceuticals Ltd., Carlina-M 2.5/1000 is a tablet whose active ingredient is Linagliptin + Metformin Hydrochloride. Metformin is a biguanide that helps control blood glucose levels. The tablet is available in the strength 2.5 mg + 1000 mg. The doctor decides the dose and course for each person.

Uses of Carlina-M 2.5/1000

It is chosen when treatment with both linagliptin and metformin hydrochloride together is suitable for the person. It is not a replacement for lifestyle measures. It is added to a proper diet and exercise plan to improve blood sugar control when treatment with both linagliptin and metformin is considered appropriate. Ask your doctor whether it is right for your condition.

How to use Carlina-M 2.5/1000

If you have questions about how to take it, ask your doctor or pharmacist. Swallow the tablet with water. Carlina-M 2.5/1000 is taken by mouth. Take Carlina-M 2.5/1000 2.5 mg + 1000 mg tablet by mouth as your doctor tells you. If you miss a dose, ask your doctor or pharmacist what to do. The dose and how often you take it are decided by your doctor, who may adjust them over time based on how well your blood sugar is controlled and how you tolerate the medicine.

Side effects of Carlina-M 2.5/1000

Low blood sugar (hypoglycemia) is more common when this medicine is used together with sulfonylureas. If you notice any unusual symptoms or feel unwell while taking it, contact your doctor. Some people may have other reactions. Contact your doctor promptly if you have severe or persistent diarrhoea, signs of low blood sugar, or any unusual symptoms. Ask your doctor or pharmacist about anything you are unsure of.

Safety and precautions

It should be used in pregnancy only if clearly needed, and caution is advised during breastfeeding. Do not start or stop this medicine without medical advice. It is also not for people with acute or chronic metabolic acidosis such as diabetic ketoacidosis, or those allergic to linagliptin or metformin. Tell your doctor if you have kidney, liver, or heart problems, or if you are scheduled for surgery or a scan with contrast dye.

Frequently asked questions

Why is Carlina-M 2.5/1000 prescribed?

It is chosen when treatment with both linagliptin and metformin hydrochloride together is suitable for the person. It is not a replacement for lifestyle measures.

How should I take Carlina-M 2.5/1000?

If you have questions about how to take it, ask your doctor or pharmacist. Swallow the tablet with water.

What are the side effects of Carlina-M 2.5/1000?

Low blood sugar (hypoglycemia) is more common when this medicine is used together with sulfonylureas. If you notice any unusual symptoms or feel unwell while taking it, contact your doctor.

Who should be careful with Carlina-M 2.5/1000?

It should be used in pregnancy only if clearly needed, and caution is advised during breastfeeding. Do not start or stop this medicine without medical advice.

Indications

This is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both Linagliptin and Metformin Hydrochloride is appropriate

Pharmacology

Linagliptin is indicated to improve glycemic control in patients with type 2 diabetes mellitus. Linagliptin is an inhibitor of DPP-4 (dipeptidyl peptidase-4), an enzyme that degrades the incretin hormones GLP-1 (glucagon like peptide-1) and GIP (glucose dependent insulinotropic polypeptide). Thus, Linagliptin increases the concentrations of active incretin hormones, stimulating the release of insulin from pancreatic beta (β) cells in a glucose-dependent manner and decreasing the secretion of glucagon from pancreatic alpha (α) cells in the circulation.

Metformin Hydrochloride is a biguanide type oral antihyperglycemic drug used in the management of type 2 diabetes. It lowers both basal and postprandial plasma glucose. Its mechanism of action is different from those of sulfonylureas and it does not produce hypoglycemia. Metformin Hydrochloride decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity by an increase in peripheral glucose uptake and utilization.

Dosage & Administration

Linagliptin & Metformin immediate release tablet: The dosage of Linagliptin & Metformin should be individualized on the basis of both effectiveness and tolerability. Maximum recommended dose of 2.5 mg Linagliptin and 1000 mg Metformin Hydrochloride twice daily with meals. Dose escalation should be gradual to reduce the gastrointestinal (GI) side effects associated with Metformin Hydrochloride use.

Recommended starting dose: In patients currently not treated with Metformin Hydrochloride, initiate treatment with 2.5 mg Linagliptin and 500 mg Metformin Hydrochloride twice daily.

In patients already treated with Metformin Hydrochloride, start with 2.5 mg Linagliptin and the current dose of Metformin Hydrochloride twice daily.

Patients already treated with Linagliptin and Metformin Hydrochloride, individual components may be switched to this combination containing the same doses of each component.

Linagliptin & Metformin extend release tablet: The dosage of this combination should be individualized on the basis of both effectiveness and tolerability, while not exceeding the maximum recommended total daily dose of Linagliptin 5 mg and Metformin Hydrochloride 2000 mg. this combination should be given once daily with a meal.

Recommended starting dose: In patients currently not treated with metformin, initiate this combination treatment with 5 mg Linagliptin/1000 mg Metformin Hydrochloride extended-release once daily with a meal.

In patients already treated with Metformin, start this combination with 5 mg of Linagliptin total daily dose and a similar total daily dose of Metformin once daily with a meal.

In patients already treated with Linagliptin & Metformin immediate release tablet, switch to extend release tablet containing 5 mg of Linagliptin total daily dose and a similar total daily dose of Metformin once daily with a meal.

5 mg Linagliptin & 1000 mg Metformin Hydrochloride extended-release tablet should be taken as a single tablet once daily. Patients using 2.5 mg Linagliptin & 1000 mg Metformin extended release tablets should take two tablets together once daily.

Interaction

Cationic drugs (amiloride, digoxin, morphine, ranitidine, trimethoprim etc.): May reduce metformin elimination.

P-glycoprotien/CYP3A4 inducer (i.e. rifampin)
: The efficacy of this medicine may be reduced when administered in combination.

Contraindications

Although Linagliptin undergoes minimal renal excretion, Metformin Hydrochloride is known to be substantially excreted by the kidney. The risk of Metformin Hydrochloride accumulation and lactic acidosis increases with the degree of renal impairment. Therefore, this combination is contraindicated in patients with renal impairment. It is also contraindicated in acute or chronic metabolic acidosis (diabetic ketoacidosis) and in hypersensitivity to Linagliptin or Metformin Hydrochloride.

Side Effects

Most common side effects are nasopharyngitis and diarrhea. Hypoglycemia is more common in patients treated with this combination and sulfonylureas.

Pregnancy & Lactation

There are no adequate and well-controlled studies in pregnant women with this combination or its individual component; so it should be used during pregnancy only if clearly needed. Caution should also be excercised when it is administered to a lactating mother.

Precautions & Warnings

In a patient with lactic acidosis who is taking Metformin, the drug should be discontinued immediately and supportive therapy promptly instituted. There have been postmarketing reports of acute pancreatitis. If pancreatitis is suspected, promptly discontinue Linagliptin & Metformin. Temporarily discontinue Linagliptin & Metformin in patients undergoing radiologic studies with intravascular administration of iodinated contrast materials or any surgical procedures necessitating restricted intake of food and fluids. Metformin may lower Vitamin B12 levels; so hematologic parameters shoud be monitored annually.

Overdose Effects

In the event of an overdose with this combination the usual supportive measures (i.e. remove unabsorbed material from the gastrointestinal tract, perform clinical monitoring, and institute supportive treatment) should be employed. Removal of Linagliptin by hemodialysis or peritoneal dialysis is unlikely but Metformin Hydrochloride is dialyzable.

During controlled clinical trials in healthy subjects, with single doses of up to 600 mg of Linagliptin (equivalent to 120 times the recommended daily dose), there were no dose-related clinical adverse drug reactions.

Overdose of Metformin Hydrochloride has occurred in case of ingestion of amounts greater than 50 grams. Hypoglycemia was reported in approximately 10% of cases, but no causal association with Metformin Hydrochloride has been established. Lactic acidosis has been reported in approximately 32% of Metformin Hydrochloride overdose cases.

Storage Conditions

Keep in a cool & dry place (below 30°C), protected from light & moisture. Keep out of the reach of children.

Alternative brands of Linagliptin + Metformin Hydrochloride

Other brands with the same generic name, cheapest first.

See all 31 brands

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.